Final answer:
Scientists utilize genetic research to create targeted therapies and must sometimes develop multiple treatments to control different symptoms of genetically varied diseases. Studies on genome mapping and the human immune system are fundamental in shaping such interventions, and collaboration among stakeholders is essential for drug discovery.
Step-by-step explanation:
Scientists can use the information gathered from studies such as genome mapping and genetic research to develop new treatments for diseases. By understanding which areas of the genome are associated with diseases like COPD, researchers can formulate targeted therapies that could potentially correct the genetic anomalies or alleviate symptoms related to the disease. Genetic research falls into the realm of both basic and applied science. Basic research helps in understanding the fundamental aspects of genes and their expressions, while applied research uses this knowledge to develop concrete interventions and treatments. Moreover, research into the human immune system aids in recognizing how biological, environmental, and social factors contribute to disease susceptibility and progression.
On considering new treatments for diseases like cancer or COPD, it is crucial to recognize that there could be multiple genetic factors at play. Therefore, scientists might indeed need to develop multiple treatments to control the various symptoms of these diseases, as a single treatment approach might not be effective for every individual due to genetic diversity.
To confirm the effectiveness of new treatments or drugs, like with a preventive medication in an experimental group in comparison to a control group, statistical tests are conducted. Such tests validate whether there is a significant reduction in disease occurrence due to the treatment, which could lead to its adoption in clinical practice. Additionally, the question of drug discovery responsibilities, such as the development of new antibiotics, rests on multiple stakeholders including governments, research institutions, and pharmaceutical companies, all of whom must collaborate for public health welfare.